Astellas oncology head says "best in class" targeted AML therapy can surpass Rydapt

1 March 2018

For years, pharmaceutical companies have struggled to develop new treatments for the second most common type of leukemia diagnosed in adults and children, acute myeloid leukemia (AML).

Now, with the advent of precision oncology, and thanks to regulators’ accelerated approval initiatives, there is new hope for patients suffering with what is one of the most deadly kinds of cancer - currently only around 20% of newly-diagnosed patients can expect to survive beyond five years.

New hope for AML patients

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK